M1415 No pos pdl1 bef ici therapy
Also known as: PD-L1 negative status, tumor PD-L1 negative, no pos pdl1 bef ici
Performance measure documenting that PD-L1 testing did not show positive expression before immunotherapy initiation. Captures negative PD-L1 status patients.
In Plain Language
Cancer tumor marker negative for immunotherapy; Low PD-L1 expression on tumor
Clinical Context
Documents negative or low PD-L1 expression in metastatic NSCLC. May require different treatment approach such as chemotherapy plus immunotherapy combination.
RVU Information
CPT M1415 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
M-codes cover quality measures and performance reporting. They are used in value-based care programs to track whether specific clinical actions were taken. Documentation must support that the measured action was performed or a valid exclusion applies.
Specialties
Frequently Asked Questions
What is CPT code M1415?
CPT M1415 (No pos pdl1 bef ici therapy) is a M Codes code. Performance measure documenting that PD-L1 testing did not show positive expression before immunotherapy initiation. Captures negative PD-L1 status patients.
Is M1415 covered by insurance?
M1415 is a temporary HCPCS code. Coverage varies by payer and may change when permanent codes are assigned. Documents negative or low PD-L1 expression in metastatic NSCLC. May require different treatment approach such as chemotherapy plus immunotherapy combination.
When is CPT M1415 used?
Documents negative or low PD-L1 expression in metastatic NSCLC. May require different treatment approach such as chemotherapy plus immunotherapy combination.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.